vs

Side-by-side financial comparison of DHT Holdings, Inc. (DHT) and TG THERAPEUTICS, INC. (TGTX). Click either name above to swap in a different company.

TG THERAPEUTICS, INC. is the larger business by last-quarter revenue ($192.6M vs $107.3M, roughly 1.8× DHT Holdings, Inc.). DHT Holdings, Inc. runs the higher net margin — 41.7% vs 12.0%, a 29.8% gap on every dollar of revenue. On growth, TG THERAPEUTICS, INC. posted the faster year-over-year revenue change (78.0% vs -24.5%).

DHT Holdings, Inc. is an independent international crude oil tanker operator that owns and manages a fleet of very large crude carriers. It offers marine transportation services for crude oil across major global trade routes, serving clients including leading oil producers, refineries, and commodity trading enterprises worldwide.

TG Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for patients with B-cell malignancies, autoimmune diseases and neurodegenerative disorders. Its core operating markets are North America and Europe, with key product segments including targeted monoclonal antibodies and oral small molecule treatments.

DHT vs TGTX — Head-to-Head

Bigger by revenue
TGTX
TGTX
1.8× larger
TGTX
$192.6M
$107.3M
DHT
Growing faster (revenue YoY)
TGTX
TGTX
+102.5% gap
TGTX
78.0%
-24.5%
DHT
Higher net margin
DHT
DHT
29.8% more per $
DHT
41.7%
12.0%
TGTX

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
DHT
DHT
TGTX
TGTX
Revenue
$107.3M
$192.6M
Net Profit
$44.8M
$23.0M
Gross Margin
80.2%
Operating Margin
44.2%
26.2%
Net Margin
41.7%
12.0%
Revenue YoY
-24.5%
78.0%
Net Profit YoY
27.3%
-1.3%
EPS (diluted)
$0.28
$0.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DHT
DHT
TGTX
TGTX
Q4 25
$192.6M
Q3 25
$107.3M
$161.7M
Q2 25
$141.1M
Q1 25
$120.9M
Q4 24
$108.2M
Q3 24
$142.1M
$83.9M
Q2 24
$73.5M
Q1 24
$63.5M
Net Profit
DHT
DHT
TGTX
TGTX
Q4 25
$23.0M
Q3 25
$44.8M
$390.9M
Q2 25
$28.2M
Q1 25
$5.1M
Q4 24
$23.3M
Q3 24
$35.2M
$3.9M
Q2 24
$6.9M
Q1 24
$-10.7M
Gross Margin
DHT
DHT
TGTX
TGTX
Q4 25
80.2%
Q3 25
82.6%
Q2 25
86.6%
Q1 25
87.1%
Q4 24
85.8%
Q3 24
88.9%
Q2 24
88.7%
Q1 24
91.4%
Operating Margin
DHT
DHT
TGTX
TGTX
Q4 25
26.2%
Q3 25
44.2%
18.2%
Q2 25
24.7%
Q1 25
7.1%
Q4 24
27.7%
Q3 24
29.7%
14.8%
Q2 24
12.0%
Q1 24
-14.6%
Net Margin
DHT
DHT
TGTX
TGTX
Q4 25
12.0%
Q3 25
41.7%
241.7%
Q2 25
20.0%
Q1 25
4.2%
Q4 24
21.6%
Q3 24
24.8%
4.6%
Q2 24
9.4%
Q1 24
-16.9%
EPS (diluted)
DHT
DHT
TGTX
TGTX
Q4 25
$0.14
Q3 25
$0.28
$2.43
Q2 25
$0.17
Q1 25
$0.03
Q4 24
$0.16
Q3 24
$0.22
$0.02
Q2 24
$0.04
Q1 24
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DHT
DHT
TGTX
TGTX
Cash + ST InvestmentsLiquidity on hand
$81.3M
$142.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.1B
$648.0M
Total Assets
$1.4B
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DHT
DHT
TGTX
TGTX
Q4 25
$142.0M
Q3 25
$81.3M
$131.6M
Q2 25
$251.9M
Q1 25
$276.2M
Q4 24
$311.0M
Q3 24
$73.8M
$341.0M
Q2 24
$217.3M
Q1 24
$209.8M
Stockholders' Equity
DHT
DHT
TGTX
TGTX
Q4 25
$648.0M
Q3 25
$1.1B
$607.2M
Q2 25
$276.4M
Q1 25
$237.3M
Q4 24
$222.4M
Q3 24
$1.0B
$192.2M
Q2 24
$177.6M
Q1 24
$160.1M
Total Assets
DHT
DHT
TGTX
TGTX
Q4 25
$1.1B
Q3 25
$1.4B
$1.0B
Q2 25
$702.6M
Q1 25
$656.7M
Q4 24
$577.7M
Q3 24
$1.5B
$586.0M
Q2 24
$401.2M
Q1 24
$373.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DHT
DHT
TGTX
TGTX
Operating Cash FlowLast quarter
$60.9M
$19.7M
Free Cash FlowOCF − Capex
$19.6M
FCF MarginFCF / Revenue
10.2%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
1.36×
0.85×
TTM Free Cash FlowTrailing 4 quarters
$-25.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DHT
DHT
TGTX
TGTX
Q4 25
$19.7M
Q3 25
$60.9M
$-23.2M
Q2 25
$7.4M
Q1 25
$-28.7M
Q4 24
$-25.6M
Q3 24
$80.1M
$-12.2M
Q2 24
$5.5M
Q1 24
$-8.2M
Free Cash Flow
DHT
DHT
TGTX
TGTX
Q4 25
$19.6M
Q3 25
$-23.2M
Q2 25
$7.4M
Q1 25
$-28.7M
Q4 24
$-25.7M
Q3 24
$-12.2M
Q2 24
Q1 24
FCF Margin
DHT
DHT
TGTX
TGTX
Q4 25
10.2%
Q3 25
-14.4%
Q2 25
5.2%
Q1 25
-23.8%
Q4 24
-23.7%
Q3 24
-14.6%
Q2 24
Q1 24
Capex Intensity
DHT
DHT
TGTX
TGTX
Q4 25
0.0%
Q3 25
0.0%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
DHT
DHT
TGTX
TGTX
Q4 25
0.85×
Q3 25
1.36×
-0.06×
Q2 25
0.26×
Q1 25
-5.67×
Q4 24
-1.10×
Q3 24
2.28×
-3.15×
Q2 24
0.80×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DHT
DHT

Segment breakdown not available.

TGTX
TGTX

Products$189.1M98%
License$3.5M2%

Related Comparisons